Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus. - Wikidata - wikimedia - TriplyDB

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

http://www.wikidata.org/entity/Q35021555

about

Multifunctional facets of retrovirus integrase Pre-exposure prophylaxis to prevent HIV infection: current status, future opportunities and challenges Preventing HIV infection: pre-exposure and postexposure prophylaxis Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV Transmission Approved Antiviral Drugs over the Past 50 Years Profile of cabotegravir and its potential in the treatment and prevention of HIV-1 infection: evidence to date Antiretrovirals for primary HIV prevention: the current status of pre- and post-exposure prophylaxis Ending the global HIV/AIDS pandemic: the critical role of an HIV vaccine.Implementation challenges for long-acting antivirals as treatment.Engineered Bispecific Antibodies with Exquisite HIV-1-Neutralizing Activity.High interest in a long-acting injectable formulation of pre-exposure prophylaxis for HIV in young men who have sex with men in NYC: a P18 cohort substudy Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Pharmacokinetics of injectable, long-acting nevirapine for HIV prophylaxis in breastfeeding infants.Using geospatial modelling to optimize the rollout of antiretroviral-based pre-exposure HIV interventions in Sub-Saharan Africa The role of dolutegravir in the management of HIV infection Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques Clinical Treatment Options Infectious Diseases: Update on PrEP Implementation, Adherence, and Advances in Delivery GSK1265744 demonstrates robust in vitro activity against various clades of HIV-1.A long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.Neutralization properties of simian immunodeficiency viruses infecting chimpanzees and gorillas.Pharmacokinetics of antiretrovirals in mucosal tissue A new hypothesis on HIV cure.Characterization of the Drug Resistance Profiles of Integrase Strand Transfer Inhibitors in Simian Immunodeficiency Virus SIVmac239.A Shot in the Arm for HIV Prevention? Recent Successes and Critical Thresholds.The mixed lineage kinase-3 inhibitor URMC-099 improves therapeutic outcomes for long-acting antiretroviral therapy The promise and pitfalls of long-acting injectable agents for HIV prevention.Potential Clinical and Economic Value of Long-Acting Preexposure Prophylaxis for South African Women at High-Risk for HIV Infection.A long-acting formulation of the integrase inhibitor raltegravir protects humanized BLT mice from repeated high-dose vaginal HIV challenges.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment.Familiarity with and Preferences for Oral and Long-Acting Injectable HIV Pre-exposure Prophylaxis (PrEP) in a National Sample of Gay and Bisexual Men in the U.S.Regulatory considerations for antiretroviral prophylaxis to prevent HIV acquisition.Nanoformulation strategies for the enhanced oral bioavailability of antiretroviral therapeutics.Formulation and pharmacology of long-acting cabotegravir.Down-regulation of human endogenous retrovirus type K (HERV-K) viral env RNA in pancreatic cancer cells decreases cell proliferation and tumor growth.The future of pre-exposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection.Long-Acting Antiretrovirals: Where Are We now?Optimal HIV Postexposure Prophylaxis Regimen Completion With Single Tablet Daily Elvitegravir/Cobicistat/Tenofovir Disoproxil Fumarate/Emtricitabine Compared With More Frequent Dosing Regimens.Tackling HIV and AIDS: contributions by non-human primate models.Cabotegravir long acting injection protects macaques against intravenous challenge with SIVmac251.

P2860

Q26795766-D9CAAAF9-4D5C-4FFF-A9D9-19665CE9FD9D Q26825641-EA67D571-9F3C-4765-93B2-46EB2C49C252 Q26828445-C5FF8DAD-2DC8-419E-AA45-B3556E1B19F4 Q27318354-FA844143-B1F2-4A0E-BD75-6F1F972B90AA Q27755387-26F3F704-96A6-429B-B201-6D4EC15D253D Q28079025-68FCD8F2-442F-4116-8908-7781CE33FAE2 Q28085433-F85C2029-E1B1-45E9-BEF5-132BC16BFF32 Q30365998-0DEE309A-AE17-4826-B04B-72CE44AAE056 Q30375397-207CD24B-0F73-4713-AF70-93513CDF3EBF Q34531219-4D5BBD73-1AE4-483D-91AD-E07AB0C701ED Q34681829-9F2C3E58-C0AD-455A-9E31-4B1548083F28 Q34726183-1BB5BB20-FA69-4DD1-8EF8-FD74909F0EFA Q34922985-55A88F93-A2DC-4BA8-9469-D248A1E26ED9 Q35067756-4BA4C6EF-B696-4994-BA77-2191540540B2 Q35121450-9D225FC0-2502-4090-8E02-56F9D797F6C4 Q35432739-9FEEB1AD-AA09-429A-A472-7B0848F94A61 Q35541521-F55FDF46-832F-46FA-A7FD-31574D4A8B0E Q35629509-348948C4-47CB-491A-BF33-B24CCB2F7517 Q35667426-C2D4AE15-444D-4AF8-985B-A0F383F97C8B Q35677620-0CB7A54A-215E-4F13-BBFF-54B0FC57EA11 Q35838594-BD69F845-0D87-4414-B33F-FA1C3529B59D Q36028475-90AEB4D0-96F4-48FF-A570-D6BFE5840C76 Q36281109-82A1FDDC-1462-4A50-B044-97E73663CF94 Q36294782-169EBCFE-0B76-4196-8D07-9D91AFB2A70C Q36505647-8D98A8DD-EF5D-4E19-829F-59281DE6221F Q36561375-BC15994F-DE6D-4F4F-815B-C1ECF1D1386D Q36816564-D3EC72BE-8AB5-4718-A9B8-58E7C2BB7B15 Q36901505-B601BFFF-6644-4CB5-9A03-5CE5A80BE60C Q36933427-4C211BED-C448-4966-9166-008D9C44DADD Q36934918-8F5E18B9-A69A-417E-BE37-21B6B3824D9D Q36995428-4095FA72-73A5-4E2D-8D6C-7A08616E30CB Q38233289-8758FDF8-7042-430B-92FB-69C4C2B0AAB8 Q38495022-27FAB000-9A17-4F55-8606-177C4F1C9175 Q38518434-6EE527F3-2A1E-429A-A6D8-FA59E404C570 Q38692314-B918E4C0-B19B-4B44-8ECF-1CC2EAECD99D Q38742497-D18C560E-0F22-4E89-A2A9-0233B05957C1 Q38902077-2E3FF56A-D18F-4A6F-8F54-7422FA3EE9B9 Q40127599-E9B8B90B-7486-450C-A07E-2130A5051137 Q40191155-5E5664B0-AA8C-4A8F-8DE4-CA7C3CF607F6 Q40429647-E0364662-5E33-4FE1-A5F3-0B2D5DE3C7D1

P2860

Long-acting integrase inhibitor protects macaques from intrarectal simian/human immunodeficiency virus.

http://www.wikidata.org/entity/Q35021555

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Long-acting integrase inhibito ...... /human immunodeficiency virus.

@ast

Long-acting integrase inhibito ...... /human immunodeficiency virus.

@en

type

label

Long-acting integrase inhibito ...... /human immunodeficiency virus.

@ast

Long-acting integrase inhibito ...... /human immunodeficiency virus.

@en

prefLabel

Long-acting integrase inhibito ...... /human immunodeficiency virus.

@ast

Long-acting integrase inhibito ...... /human immunodeficiency virus.

@en

P1433

Q35021555-DB7EDD15-5110-4F49-88A4-477764EC1A33

P1476

Q35021555-B6B10C69-7B10-43F7-AB43-EDE48E905FEC

P2093

Q35021555-36B83B34-5620-4B1B-B2EB-3B21C62BA6DA

Q35021555-889C894A-FA73-4091-8A13-F328CAAB1B97

Q35021555-8D2C5743-667A-48AF-B774-A4FACA82B7CA

Q35021555-8D76DE01-1B6A-411F-9EDF-1690A72046A9

Q35021555-925C020A-C5E4-4F60-85E1-1F639EBBEA53

Q35021555-9AD497B8-B323-4ABC-897D-2B68F45B3AB9

Q35021555-B7FE5FB3-65F5-4DEC-B8C1-BAE1940FCFBC

Q35021555-C4DBA155-A0DF-4B90-8F84-F2B974C3FAAE

Q35021555-D1DE678B-9627-4BEC-B839-5A976F4A9854

Q35021555-DCF60375-AC77-4B87-846D-B459325230F5

P2860

Q35021555-0A85CA39-8754-40FB-A36A-442B5A42C710

Q35021555-0DB38433-0390-45CA-843C-D79D8F8A76E9

Q35021555-14240BA3-575D-404B-AB48-5556B80621B3

Q35021555-182FAE5D-5F88-4192-9811-88AA6B5384F3

Q35021555-1E639C28-E823-419C-8B50-B06CEB90DA12

Q35021555-2DE024CA-69B4-4322-B525-84709BBC75BA

Q35021555-3C32A92E-0049-48D2-8C8B-3B6FADD6AB3C

Q35021555-3C3C7B61-F980-417C-B785-88135EE72264

Q35021555-4CD5A8B8-0E43-47F3-A7BF-D4D33B80C2EE

Q35021555-65B1A289-4BE0-42A7-9486-FEC753362273

P304

Q35021555-6316F907-E680-4044-B298-5F72D5D6F87B

P31

Q35021555-4200E770-BB40-40ED-9DD1-1FBA010D4797

P356

Q35021555-AA310C02-8565-4635-B7F2-8AB196DAAE50

P407

Q35021555-D94FB69F-2B43-4EB4-9EAF-9C51134D2B28

P433

Q35021555-FEA4289A-33BA-4D78-8266-BA99934A5904

P478

Q35021555-CE7EA01E-95F1-4EF5-851B-33E7403F9DD2

P50

Q35021555-4F9E7559-996D-4F07-92B1-80C03DE5CEFD

P577

Q35021555-48BC0D46-49FA-4D2B-91C4-E6DF57F06478

P698

Q35021555-D00C9C6A-092A-484F-B81E-94B77AF985F2

P932

Q35021555-04C302F3-1D02-4B1B-ABE1-439929205B28

P356

SCIENCE.1248707

P1433

P1476

Long-acting integrase inhibito ...... n/human immunodeficiency virus

@en

P2093

Agegnehu Gettie

http://www.w3.org/2001/XMLSchema#string

Cecilia Cheng-Mayer

http://www.w3.org/2001/XMLSchema#string

Chasity D Andrews

http://www.w3.org/2001/XMLSchema#string

David D Ho

http://www.w3.org/2001/XMLSchema#string

Hiroshi Mohri

http://www.w3.org/2001/XMLSchema#string

Lee Moss

http://www.w3.org/2001/XMLSchema#string

Martin Markowitz

http://www.w3.org/2001/XMLSchema#string

Rudolf P Bohm

http://www.w3.org/2001/XMLSchema#string

Susan Ford

http://www.w3.org/2001/XMLSchema#string

William R Spreen

http://www.w3.org/2001/XMLSchema#string

P2860

Primary HIV-1 infection is associated with preferential depletion of CD4+ T lymphocytes from effector sites in the gastrointestinal tract

Effectiveness of Long-Acting Reversible Contraception

Preexposure chemoprophylaxis for HIV prevention in men who have sex with men

Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women

Antiretroviral prophylaxis for HIV prevention in heterosexual men and women

Prevention of rectal SHIV transmission in macaques by daily or intermittent prophylaxis with emtricitabine and tenofovir

Preexposure prophylaxis for HIV infection among African women

Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana

Mucosal transmission and induction of simian AIDS by CCR5-specific simian/human immunodeficiency virus SHIV(SF162P3)

Long-circulating and target-specific nanoparticles: theory to practice.

P304

1151-1154

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCIENCE.1248707

http://www.w3.org/2001/XMLSchema#string

P407

P433

6175

http://www.w3.org/2001/XMLSchema#string

P478

343

http://www.w3.org/2001/XMLSchema#string

P50

Kasi Russell-Lodrigue

P577

2014-03-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24594934

http://www.w3.org/2001/XMLSchema#string

P932

4308974

http://www.w3.org/2001/XMLSchema#string